Treating Parkinson's Disease with Human Bone Marrow Mesenchymal Stem Cell Secretome: A Translational Investigation Using Human Brain Organoids and Different Routes of In Vivo Administration.

Cells · 2023 · PMC10650433 · PMID 37947643

Europe PMC DOI

hedged sentences

0.0800

closest p · 1.6× alpha

0.0800

boldest claim

The sentences

almost significantp = 0.08so close (0.05 < p ≤ 0.1)

Upon treatment, an almost significant trend (F (2,69) = 2.55, p = 0.08) in the increase in TH+ dopaminergic neurons was observed for 6-OHDA organoids treated with BM-MSC secretome when compared to the non-treated 6-OHDA organoids (Control−). 6-OHDA is a highly oxidizable dopamine analog, which can be captured through the dopamine transporters (DAT) [ 33 ].

also in 497 other papers

failed to reach statistical significanceno p-value reported

Although a smaller but similar trend was seen for the animals receiving IC secretome treatment, results failed to reach statistical significance.

also in 1,735 other papers

near-significantno p-value reported

In this context, our treatment with BM-MSC secretome was able to elicit near-significant protection specifically of the dopaminergic cell population (TH+).

also in 1,038 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.